CEVE yields 1000000.00% · ABBV yields 3.06%● Live data
📍 CEVE pulled ahead of the other in Year 1
Combined, CEVE + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CEVE + ABBV for your $10,000?
Ceres Ventures, Inc., a development stage company, focuses on the research, development, and commercialization of clean technologies for the remediation of polluted water, soil, and air. Its technologies include BluFlow Nanoparticles, a proprietary system for formulating, producing, and deploying customizable absorbent nanoparticles to specific functionality for contaminant/chemical removal and extraction of valuable elements and compounds from water based solutions; BluFlow Advanced Ultrafiltration Technology, an automated process to recover water from waste or impure streams; and BluFlow Treatment System a water and wastewater treatment solution, which incorporates the BluFlow Nanoparticles and the BluFlow Advanced Ultrafiltration Technology to remove target elements, compounds, and pollutants, as well as purify water that may be suitable for reuse. Ceres Ventures, Inc.'s products are used in water and wastewater treatment and purification, contaminated groundwater treatment, industrial wastewater treatment, and valuable elements and compounds extraction applications. The company was formerly known as PhytoMedical Technologies, Inc. and changed its name to Ceres Ventures, Inc. in November 2011. Ceres Ventures, Inc. is based in New York, New York.
Full CEVE Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.